Plus therapeutics receives $3 million award recommendation from the united states department of defense

Plus now has $23 million in active awards support for the company's targeted radiotherapeutic pipeline funding for pediatric brain cancer treatment is expected to begin in q3 2024,  pending contract finalization austin, texas, april 22, 2024 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announced it has been selected for funding by the department of defense (dod) office of the congressionally directed medical research programs (cdmrp). the award is expected to commence in q3 2024 and will support the planned expansion of the company's clinical trial for pediatric brain cancer.
pstv Ratings Summary
pstv Quant Ranking